GlassScriptPhysician profile
Eshraq Al-Jaghbeer
NPI 1184897357
$656.64
in general payments reported to CMS, 2019-2025
19 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.00 · 2024: $151 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $66.07 | 2024-2025 | Unithroid |
| Horizon Therapeutics Plc | $65.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $60.06 | 2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $60.06 | 2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.41 | 2025 | Jardiance |
| Tandem Diabetes Care, INC. | $43.93 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $42.63 | 2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $41.21 | 2024-2025 | Freestyle Libre 3 |
| Rhythm Pharmaceuticals, INC. | $30.38 | 2025 | Imcivree |
| Bayer Healthcare Pharmaceuticals INC. | $25.91 | 2025 | |
| Corcept Therapeutics | $22.72 | 2024 | Korlym |
| Lilly USA, LLC | $21.90 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $20.40 | 2024 | Crysvita |
| Ibsa Pharma INC. | $19.86 | 2025 | Tirosint, Licart, Flector |
| Sequel Med Tech, LLC | $17.03 | 2025 | Twiist |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $16.83 | 2025 | Yorvipath |
| Amgen INC. | $16.80 | 2025 | Repatha |
| Abbvie INC. | $16.47 | 2025 | |
| Astellas Pharma US INC | $15.97 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eshraq Al-Jaghbeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.